Administration of thymopentin to patients with phobic disorders improves depressed phagocytic functions

Immunopharmacology and Immunotoxicology
V CovelliE Jirillo

Abstract

Seven patients with phobic disorders were administered with a synthetic thymic extract, thymopentin (TP-5), in order to correct depressed polymorphonuclear cell (PMN) and monocyte phagocytosis and killing capacities. Subcutaneous administration (50 mg, three times weekly, for a period of 8 wks) of TP-5 resulted in a significant increase in phagocytic function with no change in the phagocytic capacity of PMN. These data support the concept that immunomodulators can achieve a correction of immune deficiencies associated with phobic disorders.

References

Jan 1, 1990·Journal of Clinical Laboratory Analysis·V CovelliE Jirillo
Feb 1, 1988·Trends in Genetics : TIG·F NagyN H Chua
Jan 1, 1988·Toxicon : Official Journal of the International Society on Toxinology·B BizziniA A Fedinec
Jan 1, 1986·Advances in Immunology·D G PayanE J Goetzl
Sep 1, 1969·The American Journal of Medicine·G L Mandell, E W Hook
Apr 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·R S Basch, G Goldstein
Mar 1, 1971·American Journal of Clinical Pathology·L T YamW H Crosby
Apr 1, 1980·The Journal of Experimental Medicine·E L ReinherzS F Schlossman

❮ Previous
Next ❯

Citations

Jan 1, 1992·Archives of Gerontology and Geriatrics·V CovelliS Antonaci
Mar 11, 1999·Journal of Receptor and Signal Transduction Research·S GonserG Folkers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.